Holdaway I.M. Factors Influencing Mortality in Acromegaly / I.M. Holdaway, R.C. Rajasoorya, G.D. Gamble // J. Clin Endocrinology Metab. — 2004. — Vol. l89. — № 2. — P. 667-674.
Sherlock M. ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly / M. Sherlock, R.C. Reulen, A.A. Alonso et al. // J Clin Endocrinol Metab. – 2009. –Vol. 94. – № 11. – P. 4216-4223
Ronchi C.L. Long-term effecs of radiotherapy on cardiovascular risk factors in acromegaly / C.L. Ronchi, E. Verrua, E. Ferrante et al. // Abstract book of European Neuroendocrine Assotiation Congress. — 2010. – PC.3. — P. 88.
Horvath E. Pathology of Acromegaly / Horvath, K. Kovacs // Neuroendocrinology. — 2006. — Vol. 83. — P. 161-165.
Melmed S. Guidelines for acromegaly management / Melmed, F.F. Casanueva, F. Cavagnini et al. // J Clin Endocrinol Metab. — 2002. — Vol. 87. — P. 4054–4058.
Sekizawa N. Acromegaly Associated with Multiple Tumors / N. Sekizawa, E. Hayakawa, K. Tsuchiya, et al. // Med. – 2009. – Vol. 48. – P. 1273-1278.
Varela-Nieto I, Chowen J.A. The growth hormone/insulin-like growth factor axis during development. Advances in experimental medicine and biology, , Springer Science+Business Media, 2005, Inc. p.421.
Bowers CY. New insights into the control of growth hormone secretion. In; Central and Peripheral Mechanisms in Pituitary disease. Ed DL Kleinberg and DR Clemmons, BioScientifica Ltd, Bristol, 2002, P. 163-175.
Root AW, Diamond FB. Regulation and Clinical Assessment of Growth Hormone Secretion. Endocrine 2004, Vol.12, N 2, P.137-145.
Cooke NE, Ray J, Watson MA, et al. Human growth hormone gene and the highly homologous growth hormone variant gene display different splicing patterns. J Clin Invest, 1998, Vol.82, P.270-275.
Goffin V, Shiverick KT, Kelly PA, Martial JA. Sequencefunction relationships within the expanding family of prolactin, growth hormone, placental lactogen and related proteins in mammals. Endocrine Reviews, 1996, Vol.17,P. 385-410.
Targets for Growth Hormone and IGF-I Action, BioScientifica Ltd, 2001, p330.
Steiner R.A., Steward J.K., Barber D, et al. Somatostatin: A physiological role in the regulation of growth hormone secretion in the adolescent male baboon. Endocrinology, 1978, Vol.102, P.1587-1594.
Patel, Y. C., M. T. Greenwood, R. Panetta, L. Demchyshyn, H. Niznik, C. B. Srikant. Mini review: the somatostatin receptor family. Life Sci. 1995, 57: 1249-1265.
Patel, Y. C. Molecular pharmacology of somatostatin receptor subtypes. Endocr. Invest. 1997, 20: 348-367.
Meriney, S. D., D. B. Gray, G. R. Pilar. Somatostatin-induced inhibition of neuronal Ca2+ current modulated by cGMP-dependent protein kinase. Nature 1994, 369: 336-339.
M?ller, E. E. Neural control of somatotropic function. Rev. 1987, 67: 962-1053.
Salmon WD Jr, Daughaday WH. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 1957; 49:825–836
Brabant G, von zur Muhlen A, Wuster C. et al. Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: Results from a multicenter study. Horm Res, 2003, Vol. 60, P.53-60.
Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev, 1995, Vol 16, P 3-34.
Silha J.V., Murphy L.J. Insulin-like growth factor binding proteins in development In: The Growth Hormone/Insulin-like Growth Factor Axis During Development. 2005. Springer Science+Business Media, Inc. p.53-89.
Guler HP, Zapf J, Schmid C, Froesch ER. Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinol 1989, V.121, P. 753-758.
Mohan S, Baylink DJ. IGF-binding proteins are multifunctional and act via IGF-dependent and independent mechanisms. J Endocrinol, 2002, Vol.175, P.19-31.
Janssen J.A., Stolk R.P., Pols H.A. et al. Serum free IGF-I, total IGF-I, IGFBP-I, and IGFBP-3 levels in an elderly population: relation to age and sex steroid levels. Clin Endocrinol (Oxf), 1998; 48:471-478.
Rees A., Scanlon M. The physiology of the growth hormone/insulin-like growth factor axis. In: Growth Hormone Deficiency in Adults. Oxford PharmaGenesisTM p. 15-28.
Van der Lely AJ, Tschop M, Heiman ML, Ghigo E. Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Grelin. Endocrine Reviews, 2004, Vol. 25., n 3, p.426-457.
Tannenbaum GS, Bowers CY. Interactions of growth hormone secretagogues and growth hormone-releasing hormone /somatostatin. Endocrine, 2001, Vol. 14, P. 21-27.
Ghigo E., Benso A, Broglio F. Grelin. Kluwer Academic Publishers, 2004, p.257
Chanoine JP. Ghrelin in Growth and Development. Horm Research, 2005, Vol. 63, P. 129-138.
Пронин В.С. Физиологическое действие гормона роста и инсулиноподобных ростовых факторов /ВС Пронин, Д.Е. Колода //.Акромегалия Под ред И.И. Дедова, Г.А. Мельниченко. Корпорация Я, 2009 г, стр.66-99.
Kontogeorgos G. Classification and Pathology of Pituitary Tumors. Endocrine.2005; 28(1):27-35.
Melmed S. Mechanisms for pituitary tumorigenesis: the plastic pituitary J Clin Invest. 2003; 112:1603-18.
Li J, Stefaneanu L, Kovacs K, et al. Growth hormone (GH) and prolactin (PRL) gene expression and immunoreactivity in GH- and PRL-producing human pituitary adenomas. Virchov Arch A Pathol Anat Histopathol 1993; 422(3):193-201.
Kato M, Inochita N, Sugiyama T et al. Differential expression of genes related to drug responsivenes between sparsely and densely granulated somatotroph adenomas. Endocrin J. 2012; 59(3):221-8.
Horvath E, Kovacs K. Pathology of Acromegaly. Neuroendocrinology. 2006; 83:161-5.
Obary A, Sano T, Ohyama K. et al. Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol. 2008; 19(2):82-91.
Wang M, Mou C, Jiang M. The characteristics of acromegalic patients with hyperprolactinemia and the differences in patients with merely GH-secreting adenomas: clinical analysis of 279 cases. Eur J Endocrinol 2012; 166(5):797-802.
Pawlikowski M, Kunert-Radek J, Radek M. Plurihormonality of pituitary adenomas in light of immunohistochemical studies. Endokrynologia Polska. 2010; 61(1):63-6.
Saeger W, Ludecke DK, Buchfelder M. et al. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol. 2007; 156:203-16.
Abe T. Effects of preoperative octreotide treatment on different subtypes of GH-secreting adenomas and outcome in one surgical centre / T. Abe, D.K. Ludecke. // Eur J Endocrinol. – 2001. –Vol. 145. – P. 137-145.
Rostomyan L., The clinical and genetic characteristics of patients with gigantism (abstract) / Rostomyan, A.F. Daly, M. Tichomirova et al //13th International Workshop on Multiple Endocrine Neoplasia liege, Belgium, 5-8 September, 2012. OR 1.2, P. 40
Marie P. Sur deux cas d’acromegalie: hypertrophie singuliere, non congenitale, des extremites superieures, inferieures et cephaliqies / P. Marie // Revue Medicale de Liege. – 1886. – Vol. 6. – P. 297–333.
Melmed Guidelines for Acromegaly Management: An Update / S. Melmed, A. Colao, A. Barkan et al. // J Clin Endocrinol Metab. — 2009. — Vol. 94. — № 5. — P. 1509-1517.
Van der Lely AJ. Acromegaly (Pathology, Diagnosis and Treatment) / A.J. van der Lely, A. Beckers, A.F. Daly et al. // 2005. — P. 40.
Burt MG. Newer options in the management of acromegaly / M.G. Burt, K.K. Ho // Intern Med J. — 2006. — Vol. 36. — № 7. — P. 437-444.
Guti?rrez L.P. Registries as a tool in evidence-based medicine: example of KIMS (Pfizer International Metabolic Database) / L.P. Guti?rrez, M. Koltowska-H?ggstr?m, P.J. J?nsson et al. // Pharmacoepidemiology and drug safety. — 2008. — Vol. 17. — P. 90-102.
Brue T. Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY / T. Brue, F. Castinetti, F. Lundgren et al. // Eur J Endocrinol. – 2009. – Vol. 161. – № 1. – P. 11-17.
Drange M.R. Pituitary Tumor Registry: A novel Clinical Resource / M.R. Drange, N.R. Fram, V. Herman-Bonert et al. // J Clin Endocrinol Metab. — 2000. — Vol. 85. — P. 168-174.
Bates PR. Wide variation in surgical outcomes for acromegaly in the UK / P.R. Bates, M.N. Carson, P.J. Trainer et al. // Clin Endocrinol (Oxf). — 2007. — Vol. 68. — P. 136-142.
Bex M. AcroBel – the Belgian registry on acromegaly: a survey of the “real-life” outcome in 418 acromegalic subjects / M. Bex, R. Abs, G. T^ Sjoen et al. // Eur J Endocrinol. — 2007. — Vol. 157. — P. 399-409.
Bolanowski M. A follow-up of 130 patients with acromegaly in a single centre / M. Bolanowski, K. Zatonska, M. Kaluzny et al. // Neuro Endocrinol Lett. – 2006. – Vol. 27. – № 6. – P. 828-832.
Cannavo S. Increased prevalence of acromegaly in a highly polluted area / S. Cannav?, F. Ferrau, M. Ragonese et al // Eur J Endocrinol. — 2010. — Vol.163. – № 4. – P. 509-513.
Chanson P. Acromegaly / P. Chanson, Salenave // Presse Med. – 2009. –Vol. 38. – № 1. – P. 92-102.
Fernandez A. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK) / A. Fernandez, N. Karavitaki, J.A. Wass / Clin. Endocrinol (Oxf). — 2010. – Vol. 72. – № 3. – P. 377-382.
Kauppinen-M?kelin R. A Nationwide Survey of Mortality in Acromegaly / R. Kauppinen-M?kelin, T. Sane, A. Reunanen et al. // J Clin Endocrinol — 2005. — Vol. 90. – №7. — P. 4081-4086.
Mestron A. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly basel on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA) / A. Mestron, S.M. Webb, R. Astorga et al. // Europ. J. Endocrinol. — 2004. — Vol. 151. — P. 1-9.
Molitvoslovova N. Russian register of patients with hypothalamo-hypophyseal disorders: update to May 2010 / N. Molitvoslovova, E. Przhiyalkovskaya, L. Rozhinskaya, G. Melnichenko // Abstract book of European Neuroendocrine Association Congress, 22-25 September, 2010. – PC-58. — P. 119.
Petrossians P. Liege Acromegaly Survey (LAS): First snapshot / P. Petrossians, P. Chanson, C. Sievers et al. // Abstract book of European Neuroendocrine Association Congress, 22-25 September. — 2010. – PC-16. — P. 94.
Reincke M. The German Acromegaly Registry: description of the database and initial results / M. Reincke, Petersenn, M. Buchfelder et al. // Experiment. Clin. Endocrinol. Diabetes. – 2006. – Vol. 114. – P. 498–505.
Schneider HJ. High prevalence of biochemical acromegaly in primary care patients with elevated insulin-like growth factor-I levels / H.J. Schneider, C. Sievers, B. Saller et al. // Clin Endocrinol (Oxf). — 2008. — Vol. 69. – № 3. – P. 432-435
Sesmilo G. Twelve years of the Spanish acromegaly registry: a historical view of acromegaly management in Spain / G. Sesmilo, S.M. Webb // J Endocrinol Nutr. — 2010. — Vol. 57. – № 2. — P. 39-42.
Vandeva S. Epidemiological characteristics of acromegaly in the Bulgarian population / Vandeva, M. Andreeva, M. Orbetsova et al. // Abstract book of European Neuroendocrine Association Congress, 22-25 September, 2010. – PC-13. — P. 93.
Rosario P.W. Frequency of acromegaly in adults with diabetes or glucose intolerance and estimated prevalence in the general population / P.W. Rosario. // Pituitary. – 2011. – Vol. 14. – № 3. – P. 217-221.
Cannavo S. Increased prevalence of acromegaly in a highly polluted area /S. Cannavo, F. Ferrau, M. Ragonese et al // Eur J Endocrinol. – 2010. –Vol. 163. — № 4. – P. 509-513
Wang M. The characteristics of acromegalic patients with hyperprolactinemia and the differences with patients with merely GH-secreting adenomas: Clinical analysis of 279 cases / M. Wang, C. Mou, M. Jiang et al. // Eur J Endocrinol. – 2012.
Kadashev B. Two cases of pituitary carcinoma / B. Kadashev, L. Astafieva // 2nd Workshop Aggressive pituitary tumors, Munich, Germany. — December 1-3, 2011. – P. 63.
Raverot G. Familial pituitary adenomas with a heterogeneous functional pattern: clinical and genetic features / Raverot, W. Arnous, A. Calender // J. Endocrinol Invest. – 2007. – Vol. 30. – № 9. – P. 787-790.
Aaltonen LA. Aryl hydrocarbon receptor-interacting protein and acromegaly / LA. Aaltonen // Horm. Res. – 2007. – Vol. 68. — № 5. – P. 127-131.
AACE Acromegaly Guidelines Task Force, AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly // Endocr Pract. – 2004. – Vol. 10. — № 3. — P. 213-25.
Nomitos P. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical cure / P. Nomitos, M. Buchfelder, R. Fahlbusch // Eur J Endocrinol. – 2005. – Vol. 152. – P. 379-387.
Giustina A. Current management practices for acromegaly: an international survey / A. Giustina, M.D. Bronstein, F.F. Casanueva et al. // Pituitary – 2010. – Vol.14. — № 2. – P. 125-133.
Кадашев Б.А. Аденомы гипофиза (клиника, диагностика, лечение), Москва, Изд-во Триада. 2007. — 367 с.
Asa S.L. The Cytogenesis and Pathogenesis of Pituitary Adenomas / S. L. Asa, Ezzat // Endocrine Reviews. — 1998. – Vol. 19. – № 6. – P. 798-827.
Puig-Domingo M, Resmini E, Gomez-Anson B. et al Magnetic resonance imaging as a predictor of response to somatostatin analog in acromegaly after surgical failure. J Clin Endocrinol Metab. 2010; 95(11):4973-8.
Hsu DW. Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence / DW. Hsu, F. Hakim, BMK. Biller et al. // J Neurosurg. – 1993. – Vol. 78. – P. 753–761.
Gandour-Edwards R. Biologic markers of invasive pituitary adenomas involving the sphenoid sinus / R. Gandour-Edwards, SB. Kapadia, IP. Janecka // Mod Pathol. – 1995. – Vol. 8. – P. 160–164.
Knosp E. Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67 / Knosp, K. Kitz, A. Perneczky // Neurosurgery. — 1989. — Vol. 25. — P. 927–930.
Spada A. Clinical, biochemical and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase / A. Spada, M.Arosio, D. Bochicchio et al. // J Clin Endocrinol Metab. – 1990. – Vol. 71. — P. 1421–1426.
Jaffrain-Rea ML. A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas / M.L. Jaffrain-Rea, D. Di Stefano, G. Minniti et al. // Endocrine-Related Cancer. — 2002. — Vol. — P. 103–113.
Thapar K. Antiproliferative effect of the somatostatin analogue treatment on growth hormone-producing pituitary tumors: results of multicenter randomized trial / Thapar, K.T. Kovacs, L. Stefaneanu et al. // Mayo Clin Proc. — 1997. — Vol. 72. — P. 893-900.
Turner H.E. Angiogenesis in pituitary adenomas – relationship to endocrine function, treatment and outcome / H.E. Turner, Z. Nagy, K.C. Gatter et al. // J Endocr. — 2000. — Vol. 165. — P. 475-481.
Gong J. Matrix metalloproteinase-9, a potential biological marker in invasive pituitary adenomas / J. Gong, Y. Zhao, R. Abdel-Fattah et al. // Pituitary. – 2008. –Vol. 11. – № 1. – P. 37-48.
Jarzembowski J. Type IV Collagen Immunostaining Is a Simple, Reliable Diagnostic Tool for Distinguishing Between Adenomatous and Normal Pituitary Glands / J. Jarzembowski, R. Lloyd, P. McKeever // Archives of Pathology and Laboratory Medicine. – 2007. – Vol. 131 – № 6. – P. 931-935.
Melmed S. Acromegaly / Melmed // The New Eng J Med. – 2006. – Vol. 355. — № 24. – P. 2558-2573.
Katznelson L. American Association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly / L. Katznelson, J.L.D. Atkinson, D.M. Cook et al. // Endocrine practice. — 2011. – Vol. 17 – № 4. – P. 1-44.
Buchfelder M., Schlaffer S-M. Modern Imaging of Pituitary Adenomas. In Pituitary Today II: New Molecular, Physiogical and Clinical Aspects/ ed by Arzt E., Guitelman M./ Front Horm Res. Basel, Karger. – 2010. — Vol. 38. — P. 109-120.
Воронцов А.В. Магнитно-резонансная томография в диагностике опухолей гипофиза / Клиническая нейроэндокринология под ред И.И. Дедова, М. 2011, стр.39-50.
Ferrari E. Age-related changes of the hypothalamic-pituitary-adrenal axis: pathophysiological correlates / E. Ferrari, L. Cravello, B. Muzzoni et al. // Eur J Endocrinol. — 2001. — Vol. — P. 319–329.
Kaufman JM. The decline of androgen levels in elderly men and its clinical and therapeutic implications / J.M. Kaufman, A. Vermeulen // Endocrine Reviews. — 2005. — Vol. 26. — 833–876.
Ferrante L. Surgical treatment of pituitary tumors in the elderly: clinical outcome and long-term follow-up / L. Ferrante, G. Trillo, E. Ramundo et al. // J Neuro-Oncology. — 2002. — Vol. — P. 185–191.
Kurosaki M. Surgical treatment of clinically non-secreting pituitary adenomas in elderly patients / M. Kurosaki, D.K. Ludecke, J. Flitsch et al. // Neurosurgery. — 2000. — Vol. — P. 843–849.
Minniti G. Surgical treatment and clinical outcome of GH-secreting adenomas in elderly patients / G. Minniti, M.L. Jaffrain-Rea, V. Esposito et al. // Acta Neurochirurgica (Wien). — 2001. — Vol. — P. 1205–1211.
Turner HE. Pituitary tumours in the elderly: a 20-year experience / H.E. Turner, C.B.T. Adams, J.A.H. Wass // Eur J Endocrinol. — 1999. — Vol. — P. 383–389.
Besser GM. Predictors and rates of treatment-resistant tumor growth in acromegaly / G.M. Besser, P. Burman, A.F. Daly // Eur J. Endocrinol.- 2005.- Vol. 153. — №2.- P. 187-193.
Duran- Prado M. Potential Inhibitory Role for the New Truncated Variant of Somatostatin Receptor 5, sst5TMD4, in Pituitary Adenomas Poorly Responsive to Somatostatin Analogs. /M. Duran-Prado, A. Saveanu, R.M.J. Luque. //J Clin Endocrinol Metab. – 2010. –Vol. 95. — N. 5. — P. 2497- 2502.
Bronstein M.D. Acromegaly: Molecular Expression of Somatostatin Receptor Subtypes and Treatment Outcome /M. Bronstein // Pituitary Today (Molecular, Physiological and Clinical Aspects) ed. by Arzt, M. Bronstein, M. Guitelman, 2006; p. 129-134.
Corbetta S., Ballare E., Mantovani G et al. Somatostatin receptor subtype 2 and 5 in human GH-secreting pituitary adenomas: analysis of gene sequence and mRNA expression. / S. Corbetta, Ballare, G. Mantovani et al // Eur J Clin Invest. – 2001. – Vol. 31. — P. 208-214.
Takei M. Immunohistochemical detection of Somatostatin Receptor (SSTR) Subtypes 2A and 5 in Pituitary Adenoma from Acromegalic Patients: Good Correlation with Preoperative Response to Octreotide. /M. Takei. M. Suzuki, H. Kajiva et al. // Endocrin Pathol. – 2007. — Vol.18. – N.4. – P.208-216.
Taboada F. Quantitative analysis of somatostatin receptor subtypes (1–5) gene exp ression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR / G.F. Taboada, R.M. Luque , L.V. Neto et al. // Eur J Endocrinol. — 2008. — Vol. 158. – № 3. — P. 295-303.
Obary A. Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form / A. Obari, T. Sano, K. Ohyama et al. // Endocr Pathol. — 2008. — Vol. 19. – № 2. — P. 82-91.
Fougner S.L. The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma / S.L. Fougner, O.C. Bogota, J.P. Berg et al. // Clin Endocrinol (Oxf). — 2008. — Vol. 68. — P. 458-465.
Knutzen R. The Cost of Medical Care for the Acromegalic Patient / R. Knutzen, Ezzat // Neuroendocrinology. — 2006. — Vol. 83. — P. 139-144.
Martinez-Delgado I.A. Acromegaly. Report of 84 cases / I.A. Martinez-Delgado, G. Gomez- Martinez. // Rev. Med Inst Mex Seguro Soc. – 2008. – Vol. 46. – № 3. – P. 311-314.
Barkan A.L. Radiotherapy in acromegaly: the argument against / A.L. Barkan // Clin Endocrinol. — 2003. — Vol. 58. — P. 132-135.
Barkan A.L. Pituitary Irradiation Is Ineffective in Normalizing Plasma Insulin-Like Growth Factor I in Patients with Acromegaly / A.L. Barkan, I. Halasz, K.J. Dornfeld et al. // J Clin Endocrinol Metab. — 1997. — Vol. 82. — № 10. — P. 3187-3191.
Григорьев А.Ю., Азизян В.Н. Эндоскопическая хирургия аденом гипофиза. Практическое руководство для врачей под ред. И.И. Дедова, Москва, 2011.
Kaltsas GA. Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity / G.A. Kaltsas, A.M. Isidori, D. Florakis et al. // J Clin Endocrinol Metab. — 2001. — Vol. 86. — P. 1645–1652.
Colao A. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly / A. Colao, R. Attanasio, R Pivonello et al. // J Clin Endocrinol Metab. — 2006. — Vol. 91. — P. 85–92.
Del Porto L.A. Treatment of persistent and recurrent acromegaly / L.A. Del Porto, S.V. Liubinas, A.H. Kaye // J. Clin. Neurosci. – 2011. — Vol. 18. – № 2. – P. 181-190.
Karavitaki N. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide / N. Karavitaki, H.E. Turner, C.B. Adams et al. // Clin Endocrinol (Oxf). — 2008. — Vol. 68. — P. 970–975.
Petrossians P. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs / P. Petrossians, L. Borges-Martins, C. Espinoza et al. // Eur J Endocrinol. — 2005. — Vol. 152. — P. 61–66.
AACE Acromegaly Guidelines Task Force, AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly // Endocr Pract. — 2004. — Vol. 10. — № 3. — P. 213-225.
Beauregard C. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly / C. Beauregard, U. Truong, J. Hardy et al. // Clin Endocrinol (Oxf). — 2003. — Vol. 58. — P. 86-91.
Petersenn S. Results of surgical and somatostatin analog therapies and their combination in acromegaly: a retrospective analysis of the German Acromegaly Register / Petersenn, M. Buchfelder, M. Reincke et al. // Eur J Endocrinol. — 2008. — Vol. 159. – № 5. — P. 525-532.
Sheehan J.M. Transsphenoidal surgery for pituitary adenoma in elderly patients / J.M. Sheehan, G.L. Douds, K. Hill // Acta Neurochir. — 2008. — Vol. 150. – № 6. – P. 571-574.
Shimon I. Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients / I. Shimon, Z.R. Cohen, Z. Ram et al. // — 2001. — Vol. 48. — P. 1239–1243.
Krzentowska-Korek A. Efficacy and complications of neurosurgical treatment of acromegaly / A. Krzentowska-Korek, F. Golkowski, A. Baldys-Waligorska et al. // Pituitary. – 2011. – Vol.14. – № 2. – P. 157-162.
Brada M. Cerebrovascular mortality in patients with pituitary adenoma / M. Brada, S. Ashley, D. Ford et al. // Clin Endocrinol (Oxf). – 2002. – Vol. 57. – P. 713–717.
Berkmann S. Sarcoma of the sella after radiotherapy for pituitary adenoma / Berkmann, M. Tolnay, D. Hanggi et al. // Acta Neurochir (Wien) – 2010. – Vol. 152. – № 10. – P. 1725-1735.
Erfurth E.M. Risk factors for cerebrovascular deaths in patients operated and irradiated for pituitary tumors / E.M. Erfurth, B. Bulow, G. Svahn-Tapper et al. // J Clin Endocrinol Metab. – 2002. – Vol. 87. – P. 4892–4899.
Minniti G. Diagnosis and management of pituitary tumours in the elderly: a review based on personal experience and evidence of literature / G. Minniti, V. Esposito, M. Piccirilli et al. // Eur J Endocrinol. — 2005. — Vol. 153. — № 6. — P. 723-735.
Vik-Mo E.O. Gamma knife stereotactic radiosurgery for acromegaly / E.O. Vik-Mo, M. Oksnes, P.H. Pedersen et al. // Eur J Endocrinol. – 2007. – Vol. 157. – № 3. – P. 255-263.
Abs R. Cabergoline in the treatment of acromegaly: a study in 64 patients / Abs, J. Verhelst, D. Maiter et al. // J Clin Endocrinol Metab. — 1998. — Vol. 83. — P. 374-378.
Besser GM. Medical management of acromegaly with bromocriptine. Effects of continuous treatment for over three years / G.M. Besser, J.A. Wass // Med J Australia. – 1978. — Vol. 2. — P. 31-33.
Verhelst J.A. Remission of acromegaly following long-term therapy with cabergoline: report of two cases / J.A. Verhelst, P.J. Abrams, R. Abs // Pituitary — 2008. – Vol.11. – № 1. – P. 103-107.
Vilar L. Substantial shrinkage of adenomas cosecreting growth hormone and prolactin with use of cabergoline therapy / L. Vilar, M.A. Czepielewsk, L.A. Naves et al. // Endocr Pract. — 2007. — Vol. 13. – № 4. — P. 396-402.
Melmed Guidelines for Acromegaly Management: An Update / S. Melmed, A. Colao, A. Barkan et al. // J Clin Endocrinol Metab. — 2009. — Vol. 94. — № 5. — P. 1509-1517.
Colao A. Effect of different dopaminergic agents in the treatment of acromegaly / A. Colao, D. Ferone, P. Marzullo et al. // J Clin Endocrinol Metab. — 1997. — Vol. 82. — P. 518-523.
Cozzi R. Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? / R. Cozzi, R. Attanasio, M. Barausse et al. // Eur J Endocrinol. — 1998. — Vol. 139. — P. 516–521.
Cozzi R. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status / R. Cozzi, R. Attanasio, S. Lodrini et al. // Clin Endocrinol (Oxf). — 2004. — Vol. 61. — P. 209–215.
Marzullo P. Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients / P. Marzullo, D. Ferone, C. Di Somma et al. // — 1999. — Vol. 1. — P. 115–120.
Selvarajah D. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly / D. Selvarajah, J. Webster, R. Ross et al. // Eur J Endocrinol. — 2005. — Vol. 152. — P. 569–574.
Wagenaar AH. Dynamics of the acute effects of octreotide, bromocriptine and both drugs in combination on growth hormone secretion in acromegaly / H. Wagenaar, A.G. Harris, A.J. van der Lely et al. // Acta Endocrinol (Copenh). — 1991. — Vol. 125. — P. 637–642.
Bevan JS. Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly / J.S. Bevan // J Clin Endocrinol Metab. — 2005. — Vol. 90. — P. 1856–1863.
Bruns J. F. Tissue distribution of somatostatin receptor subtype messenger ribonucleic acid in the rat / J. F. Bruns, Y. Xu, J. Song et al. // — 1993. — Vol. 133. — P. 2561-2567.
Meriney S.D. Somatostatin-induced inhibition of neuronal Ca2+ current modulated by cGMP-dependent protein kinase / S.D. Meriney, D.B. Gray, G.R. Pilar // — 1994. — Vol. 369. — P. 336-339.
Thapar K. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody / K. Thapar, K. Kovacs, B.W. Scheithauer et al. // — 1996. — Vol. 38. — P. 99–107.
Carlsen S. Preoperative Octreotide Treatment in Newly Diagnosed Acromegalic Patients with Macroadenomas Increases Cure Short-Term Postoperative Rates: A Prospective, Randomized Trial / Lund-Johansen, T. Schreiner, S. Aanderud et al. // J Clin Endocrinol Metab. — 2008. — Vol. 93. — № 8. – P. 2984-2990.
Losa M. Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas / M. Losa, E Ciccarelli, P. Mortini et al. // J Clin Endocrinol Metab. — 2001. — Vol. 86. — P. 5194-5200.
Pokrajac A. Pituitary-independent effect of octreotide on IGF-I generation / A. Pokrajac, J. Frystyk, A. Flyvbjerg et al. // Eur J Endocrinol. — 2009. – Vol. 160. – № 4. – P. 543-548.
Schopohl J. Efficacy and Acceptability of Lanreotide Autogel 120 mg at Different Dose Intervals in Patients with Acromegaly Previously Treated with Octreotide LAR. / J. Shopohl, C.J. Strasburger, D. Caird et al. //Experimental and Clinical Endocrinology & Diabetes. -2011. – Vol. 119. – P. 156-162.
Мельниченко Г.А.. В.С. Пронин, Марова Е.И., Клиническая эффективность аналога соматостатина длительного действия «Октреотид-депо» у больных акромегалией /Г.А. Мельниченко, В.С. Пронин, Е.И. Марова // Фарматека 2007, N 11, стр.66-69
Maiza JC. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa / J.C. Maiza, D. Vezzosi, M. Matta et al. // Clin Endocrinol (Oxf). — 2007. — Vol. 67. — P. 282–289.
MurrayD. A Critical Analysis of Clinically Available Somatostatin Analog Formulations for Therapy of Acromegaly / R.D. Murray, S. Melmed // J Clin Endocrinol Metab. – 2008. – Vol. 93. – № 8. – P. 2957-2967.
Paisley A.N. Treatment of acromegaly improves quality of life, measured by AcroQol / A.N. Paisley, S.V. Rowles, M.E. Roberts et al. // Clin Endocrinol (Oxf). – 2007. – Vol. 67. – № 3. – P. 358-362.
Bevan JS. The anti-tumoral effects of somatostatin analog therapy in Acromegaly / J.S. Bevan // J Clin Endocrinol Metab. — 2005. — Vol. 90. — P. 1856-1863.
Caron P. Efficacy of the new long-acting formulation of lanreotide (lanreotide autogel) in the management of acromegaly / P. Caron, A. Beckers, D.R. Cullen et al. // J Clin Endocrinol Metab. — 2002. — Vol. 87. — P. 99-104.
Ben-Shlomo A. Pasireotide – a somatostatin analog for the potential tratment of acromegaly, neuroendocrine tumors and Cushings disease / A. Ben-Shlomo, S. Melmed // IDrugs. – 2007. – Vol. 10. — № 12. – P. 885-895.
Ferone D. Novel chimeric somatostatin analogs: facts and perspectives / D. Ferone, A. Saveanu, M.D. Culler et al. // Eur J Endocrinol. — 2007. — Vol. 156. — № 1. — P. 23-28.
Fleserio M. Pasireotid LAR Versus Octreotide LAR in Patients with Acromegaly: Double-Blind, Crossover, Extension Period to a Randomized, Double-Blind, Multicenter, Phase III Study. / M. Fleserio, M. Sheppard, MD Bronstein et al. //15th International Congress of Endocrinology and 14th European Congress of Endocrinology, Florence, Italy, 5-9 May 2012.
Clemmons D.R. Optimizing Control of Acromegaly: Integrating a Growth hormone Receptor Antagonist into the Treatment Algorithm / D.R. Clemmons, K. Chihara, P.U. Freda et al. // J Clin Endocrinol Metab. – 2003. – Vol. 88. – № 10. – P. 4759-4767.
De Marinis L. Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patiens with active acromegaly partially resistant to SSA / L. De Marinis, A. Bianchi, A. Fusco et al. // Pituitary. – 2007. – Vol. 10. – № 3. – P. 227-232.
Trainer P.J. Treatment of Acromegaly with the Growth Hormone-Receptor Antagonist Pegvisomant / P.J. Trainer, W.M. Drake, L. Katznelson et al. // New England J Medicine. – 2000. – Vol. 342. – № 16. – P. 1171-1177.
Van der Lely A.J. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist / A.J. van der Lely, R.K. Nutson, P.J. Trainer et al. // Lancet. — 2001. – Vol. 358. – № 9725. – P. 1754-1759.
Jallad R.S. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution / R.S. Jallad, N.R. Musolino, L.R. Salgado et al. // Clin Endocrinol (Oxf) – 2005. – Vol. 63. – № 2. – P. 168-175.
Casarini A.P. Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment / A.P. Casarini, R.S. Jallad, E.M. Pinto et al. // Pituitary. – 2009. – Vol. 12. — № 4. – P. 297-303.
Colao A. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients / A. Colao, R. Pivonello, R.S. Auriemma et al. //J Clin Endocrinol Metab. — 2006. — Vol. 91. — P. 2112-2118.
Colao A. Beneficial effect of dose escalation of Octreotide-Lar as first-line therapy in patients with acromegaly / A. Colao, R. Pivonello, R.S. Auriemna et al. // Eur. J Endocrinol. — 2007. — Vol. 157. — P. 579-587.
Florio T. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro / T. Florio, S. Thellung, A. Corsaro et al. // Clinical Endocrinology. — — Vol. 59. — P. 115–128.
Freda PU. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis / U. Freda, L. Katznelson, A.J. van der Lely et al. // J Clin Endocrinol Metab. — 2005. — Vol. 90. — P. 4465–4473.
Melmed S. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly / Melmed, R. Sternberg, D. Cook et al. // J Clin Endocrinol Metab. — 2005. — Vol. 90. — P. 4405–4410.
Ozbek M. Disappeareance of a GH secreting macroadenoma during long-term somatostatin analoque administration / M. Ozbek, M. Erdogan, E Akbai et al. // Exp Clin Endocrinol Diabetes. – 2009. – Vol. 117. – № 7. – P. 309-311.
Resmini E. Rapid Pituitary Shrinkage with Dissociation between Antiproliferative and Antisecretory Effects of a Long-Acting Octreotide in an Acromegalic Patient / E. Resmini, P. Dadati, J-L. Ravetti et al. // J Clin Endocrinol. — 2007. — Vol. 92. – № 5. — P. 1592-1599.
Pisarek H. Expression of somatostatin receptor subtypes in human pituitary adenomas – immunohistochemical studies / H. Pisarek, M. Pawlikowski, J. Kunert-Radek et al. // Endocrinol. Pol. – 2009. — Vol. 60. – № 4. – P. 240-251.
Bronstein M.D. Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome / M.D. Bronstein // Front Horm Res. — — Vol. 35. — P. 129–134.
Schofl C., Franz H., Grussendorf M. et al /Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register. //Eur J Endocrinol. 2013. – Vol. 168. – P. 39-47.
Zatelli M. C. Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds / M. C. Zatelli, M.R. Ambrosio, M. Bondanelli et al. // Eur J Endocrinol. – 2007. — Vol. 156. – Issue Suppl 1. – P. 29-35.
Pl?ckinger Selective Loss of Somatostatin Receptor 2 in Octreotide-Resistant Growth Hormone-Secreting Adenomas / U. Pl?ckinger, S. Albrecht, C. Mawrin et al. // J Clin Endocrinol Metab. – 2008. — Vol. 93. — № 4. – P. 1203-1210.
Amato G. Long-term effects of lanreotide SR and octreotide LAR on tumor shrinkage and GH hypersecretion in patients with previously untreated acromegaly / G. Amato, G. Mazziotti, M. Rotondy et al. // Clin. Endocrinol. (Oxf). – 2002. – Vol. 56. – P. 65-71.
Cozzi R. Treatment of acromegaly with SS analogues: should GH and IGF-I target levels be lowered to assert a tight control of the disease? / R. Cozzi, R. Attanasio, S. Grottoli et al. // J. Endocrinol. Invest. – 2004. – Vol. 27. – P. 1040-1047.
Gola M. Resistance to somatostatin analogs in acromegaly: an evolving concept? / M. Gola, Bonadonna, G. Mazziotti et al. // J Endocrinol Invest. — 2006. — Vol. 29. — P. 86–93.
Colao A. Beneficial effect of dose escalation of Octreoti-Lar as first-line therapy in patients with acromegaly / A. Colao et al // Eur J Endocrinol. — 2007. — Vol. 157. – P. 579-587.
Giustina A. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomized trial / A. Giustina, Bonadonna, G. Bugari et al // Eur J Endocrinol. – 2009. – Vol. 161. – P. 331-338.
Carmichael Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefits.// Patient Preference and Adherence. 2012. – Vol.6. – P. 73-82.
Fleseriu M. Clinical efficacy and safety resuts for dose escalation of somatostatin receptor ligands in patients wih acromegaly: a literature review. Springer, Pituitary. DOI 10.1007/s11102-010-0282-z. Published online: 2010.
Cozzi R. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status / R. Cozzi, R. Attanasio, S. Lodrini et al. // Clin Endocrinol (Oxf). — 2004. — Vol. 61. — P. 209–215.
Losa M. Medical treatmen of aggressive pituitary tumors: temozolomide / M. Losa, C. Piani, P. Mortini // 2nd Workshop Aggressive pituitary tumors, Munich, Germany, December 1-3, 2011. – P. 32.
Tulipano G. Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone secreting adenoma cells in vitro / G.Tulipano, C. Bonfanti, G. Melani et al. // Neuroendocrinology. – 2001. – Vol. 73. — P. 344-351.
Ferone D. Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy / D. Ferone, W.W. de Herder, R. Pivonello et al. // J Clin Endocrinol Metab. – 2008. – Vol. 93. – P. 1412–1417.
Annamalai AK .A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. /AK. Annamalai, A. Webb, N. Kandasamy et al. //J Clin Endocrinol Metab. – 2013. – Vol. 98. – N.3. – P.1040-50.
Adelman DT. Acromegaly: the disease, its impact on patients, and managing the burden of long-term treatment /Adelman D.T., Liebert KJP, Nachtigall LB et al. // Int J Gen Med. 2013 . – Vol. 6. –P. 31–38.
Giustina A. Criteria for Cure of Acromegaly: A Consensus Statement / Giustina et al. // Clin Endocrinol Metab. — 2000. – Vol. 85. – № 2. – P. 526-529.
Melmed S. Guidelines for acromegaly management / Melmed, F.F. Casanueva, F. Cavagnini et al. // J Clin Endocrinol Metab. – 2002. – Vol. 87. – P. 4054–4058.
Giustina A. Diagnosis and treatment of acromegaly complications / A. Giustina, F.F. Casanueva, F. Cavagnini et al. // J Endocrinol Invest. – 2003. – Vol. 26. – P. 1242–1247.
AACE Acromegaly Guidelines Task Force, AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly // Endocr Pract. — 2004. — Vol. 10. — № 3. — P. 213-225.
Melmed S. Consensus statement: medical management of acromegaly / S. Melmed et al. // Eur J — 2005. – Vol. 153. — P. 737–740.
Giustina A. Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults / Giustina, A. Barkan, P. Chanson et al. // J. Endocrinol. Invest. – 2008. – Vol. 31. – P. 820-838.
Melmed S. Guidelines for acromegaly management: an update / Melmed, A. Colao, A. Barkan et al. // J Clin Endocrinol Metab. – 2009. – Vol. 94. – P. 1509–1517.
Melmed S. A consensus on the diagnosis and treatment of acromegaly /S. Melmed, F.F. Casanueva, A. Klibanski et al//Pituitary. 2012 Aug 18. [Epub ahead of print]
Sherlock M. Monitoring disease activity using growth hormone and insulin like growth factor-I in the follow up of 501 patients with acromegaly /M. Sherlock, A.A. Aragon, R.C. Reulen et al. //Clin. Endocrinol (Oxf). – 2009. – Vol. 71. – № 1. – P. 74-81.
Katznelson L. American Association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly / L. Katznelson, J.L.D. Atkinson, D.M. Cook et al. // Endocrine practice. — 2011. – Vol. 17 – № 4. – P. 1-44.
